Regeneron Pharmaceuticals And Sanofi Announce That The FDA Has Approved Dupixent (Dupilumab) For Use With Other Medicines To Treat Chronic Rhinosinusitis With Nasal Polyposis In Adults Whose Disease Is Not Controlled